{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:17:32Z","timestamp":1788383852646,"version":"build-2803163510"},"reference-count":56,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2016,8,11]],"date-time":"2016-08-11T00:00:00Z","timestamp":1470873600000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccby_termsofuse.html"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/CG\/013\/2013"],"award-info":[{"award-number":["NMRC\/CG\/013\/2013"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/TCR\/011-NUHS\/2014"],"award-info":[{"award-number":["NMRC\/TCR\/011-NUHS\/2014"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pyrazinamide (PZA) is a critical component of first- and second-line treatments of tuberculosis (TB), yet its mechanism of action largely remains an enigma. We carried out a genetic screen to isolate Mycobacterium bovis BCG mutants resistant to pyrazinoic acid (POA), the bioactive derivative of PZA, followed by whole genome sequencing of 26 POA resistant strains. Rather than finding mutations in the proposed candidate targets fatty acid synthase I and ribosomal protein S1, we found resistance conferring mutations in two pathways: missense mutations in aspartate decarboxylase panD, involved in the synthesis of the essential acyl carrier coenzyme A (CoA), and frameshift mutations in the vitro nonessential polyketide synthase genes mas and ppsA-E, involved in the synthesis of the virulence factor phthiocerol dimycocerosate (PDIM). Probing for cross resistance to two structural analogs of POA, nicotinic acid and benzoic acid, showed that the analogs share the PDIM- but not the CoA-related mechanism of action with POA. We demonstrated that POA depletes CoA in wild-type bacteria, which is prevented by mutations in panD. Sequencing 10 POA-resistant Mycobacterium tuberculosis H37Rv isolates confirmed the presence of at least 2 distinct mechanisms of resistance to the drug. The emergence of resistance through the loss of a virulence factor in vitro may explain the lack of clear molecular patterns in PZA-resistant clinical isolates, other than mutations in the prodrug-converting enzyme. The apparent interference of POA with virulence pathways may contribute to the drug\u2019s excellent in vivo efficacy compared to its modest in vitro potency.<\/jats:p>","DOI":"10.1021\/acsinfecdis.6b00070","type":"journal-article","created":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T01:13:38Z","timestamp":1468199618000},"page":"616-626","source":"Crossref","is-referenced-by-count":96,"title":["Pyrazinamide Resistance Is Caused by Two Distinct\nMechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence\nFactor Synthesis"],"prefix":"10.1021","volume":"2","author":[{"given":"Pooja","family":"Gopal","sequence":"first","affiliation":[{"name":"National University of Singapore , Yong Loo Lin School of Medicine, , ,","place":["Singapore, Republic of Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Yee","sequence":"additional","affiliation":[{"name":"National University of Singapore , Yong Loo Lin School of Medicine, , ,","place":["Singapore, Republic of Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jickky","family":"Sarathy","sequence":"additional","affiliation":[{"name":"National University of Singapore , Yong Loo Lin School of Medicine, , ,","place":["Singapore, Republic of Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Liang","family":"Low","sequence":"additional","affiliation":[{"name":"National University of Singapore , Yong Loo Lin School of Medicine, , ,","place":["Singapore, Republic of Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jansy P.","family":"Sarathy","sequence":"additional","affiliation":[{"name":"Rutgers\u2500New Jersey Medical School Public Health Research Institute, , , ,","place":["Newark, New Jersey, United States, 07103"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firat","family":"Kaya","sequence":"additional","affiliation":[{"name":"Rutgers\u2500New Jersey Medical School Public Health Research Institute, , , ,","place":["Newark, New Jersey, United States, 07103"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ve\u0301ronique","family":"Dartois","sequence":"additional","affiliation":[{"name":"Rutgers\u2500New Jersey Medical School Public Health Research Institute, , , ,","place":["Newark, New Jersey, United States, 07103"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gengenbacher","sequence":"additional","affiliation":[{"name":"National University of Singapore , Yong Loo Lin School of Medicine, , ,","place":["Singapore, Republic of Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dick","sequence":"additional","affiliation":[{"name":"National University of Singapore , Yong Loo Lin School of Medicine, , ,","place":["Singapore, Republic of Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2016,7,11]]},"reference":[{"key":"2026090216314999500_cit1","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0041-3879(85)90040-6","article-title":"The action of antituberculosis drugs\nin short-course chemotherapy","volume":"66","author":"Mitchison","year":"1985","journal-title":"Tubercle"},{"key":"2026090216314999500_cit2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S1473-3099(13)70328-1","article-title":"New antituberculosis\ndrugs, regimens, and adjunct therapies: needs, advances, and future\nprospects","volume":"14","author":"Zumla","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"2026090216314999500_cit3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/microbiolspec.MGM2-0023-2013","article-title":"Mechanisms of Pyrazinamide Action and Resistance","volume":"2","author":"Zhang","year":"2014","journal-title":"Microbiol. Spectrum"},{"key":"2026090216314999500_cit4","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/nm0696-662","article-title":"Mutations in pncA,\na gene encoding pyrazinamidase\/nicotinamidase, cause resistance to\nthe antituberculous drug pyrazinamide in tubercle bacillus","volume":"2","author":"Scorpio","year":"1996","journal-title":"Nat. Med."},{"key":"2026090216314999500_cit5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1021\/id500028m","article-title":"Host-Mediated Bioactivation of Pyrazinamide:\nImplications for Efficacy, Resistance, and Therapeutic Alternatives","volume":"1","author":"Via","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"2026090216314999500_cit6","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1128\/JB.181.7.2044-2049.1999","article-title":"Role of Acid pH and\nDeficient Efflux of Pyrazinoic Acid in Unique Susceptibility of Mycobacterium\ntuberculosis to Pyrazinamide","volume":"181","author":"Zhang","year":"1999","journal-title":"J. Bacteriol."},{"key":"2026090216314999500_cit7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/jac\/dkg287","article-title":"Susceptibility\nof Mycobacterium tuberculosis to weak acids","volume":"52","author":"Zhang","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"2026090216314999500_cit8","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int. J. Tuberc Lung Dis"},{"key":"2026090216314999500_cit9","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/79558","article-title":"Pyrazinamide\ninhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis","volume":"6","author":"Zimhony","year":"2000","journal-title":"Nat. Med."},{"key":"2026090216314999500_cit10","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1128\/JB.184.8.2167-2172.2002","article-title":"Effects\nof Pyrazinamide on Fatty Acid Synthesis by Whole Mycobacterial Cells\nand Purified Fatty Acid Synthase I","volume":"184","author":"Boshoff","year":"2002","journal-title":"J. Bacteriol."},{"key":"2026090216314999500_cit11","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.1208813","article-title":"Pyrazinamide Inhibits Trans-Translation\nin Mycobacterium tuberculosis","volume":"333","author":"Shi","year":"2011","journal-title":"Science"},{"key":"2026090216314999500_cit12","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1128\/JCM.00620-12","article-title":"Gene Sequencing for Routine Verification of Pyrazinamide\nResistance in Mycobacterium tuberculosis: a Role\nfor pncA but Not rpsA","volume":"50","author":"Alexander","year":"2012","journal-title":"J. Clin Microbiol"},{"key":"2026090216314999500_cit13","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1128\/AAC.04541-14","article-title":"Phenotypic and Genotypic Characterization\nof Pyrazinamide Resistance among Multidrug-resistant Tuberculosis\nisolates in Zhejiang, China","volume":"59","author":"Xia","year":"2015","journal-title":"Antimicrob. Agents\nChemother."},{"key":"2026090216314999500_cit14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.5588\/ijtld.14.0305","article-title":"Mutations in the pncA and rpsA genes among 77 Mycobacterium tuberculosis isolates in Kazakhstan","volume":"19","author":"Akhmetova","year":"2015","journal-title":"Int. J. Tuberc Lung Dis"},{"key":"2026090216314999500_cit15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/AAC.41.3.540","article-title":"Characterization of pncA mutations\nin pyrazinamide-resistant Mycobacterium tuberculosis","volume":"41","author":"Scorpio","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090216314999500_cit16","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1038\/emi.2013.38","article-title":"Mutations in panD encoding aspartate\ndecarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis","volume":"2","author":"Zhang","year":"2013","journal-title":"Emerging\nMicrobes Infect."},{"key":"2026090216314999500_cit17","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1038\/emi.2014.61","article-title":"Aspartate\ndecarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis","volume":"3","author":"Shi","year":"2014","journal-title":"Emerging Microbes Infect."},{"key":"2026090216314999500_cit18","doi-asserted-by":"publisher","first-page":"7258","DOI":"10.1128\/AAC.04028-14","article-title":"Pantothenate and Pantetheine Antagonize the Antitubercular\nActivity of Pyrazinamide","volume":"58","author":"Dillon","year":"2014","journal-title":"Antimicrob. Agents\nChemother."},{"key":"2026090216314999500_cit19","doi-asserted-by":"publisher","first-page":"5186","DOI":"10.1128\/AAC.05385-11","article-title":"Systematic\nAnalysis of Pyrazinamide-Resistant Spontaneous Mutants and Clinical\nIsolates of Mycobacterium tuberculosis","volume":"56","author":"Stoffels","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090216314999500_cit20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/ng.2878","article-title":"Evolution\nand transmission of drug-resistant tuberculosis in a Russian population","volume":"46","author":"Casali","year":"2014","journal-title":"Nat. Genet."},{"key":"2026090216314999500_cit21","doi-asserted-by":"publisher","first-page":"e01819","DOI":"10.1128\/mBio.01819-14","article-title":"Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study","volume":"5","author":"Miotto","year":"2014","journal-title":"mBio"},{"key":"2026090216314999500_cit22","doi-asserted-by":"publisher","DOI":"10.1093\/femspd\/ftv037","article-title":"Pyrazinamide resistance in Mycobacterium tuberculosis fails to bite?","volume":"73","author":"den Hertog","year":"2015","journal-title":"Pathog. Dis."},{"key":"2026090216314999500_cit23","doi-asserted-by":"publisher","first-page":"10063","DOI":"10.1038\/ncomms10063","article-title":"Rapid antibiotic-resistance\npredictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis","volume":"6","author":"Bradley","year":"2015","journal-title":"Nat. Commun."},{"key":"2026090216314999500_cit24","first-page":"748","article-title":"Activation of pyrazinamide\nand nicotinamide in acidic environments in vitro","volume":"70","author":"McDermott","year":"1954","journal-title":"Am. Rev. Tuberc"},{"key":"2026090216314999500_cit25","doi-asserted-by":"publisher","first-page":"7320","DOI":"10.1128\/AAC.00967-15","article-title":"Uncoupling Environmental\npH and Intrabacterial Acidification from Pyrazinamide Susceptibility\nin Mycobacterium tuberculosis","volume":"59","author":"Peterson","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090216314999500_cit26","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/BF01779121","article-title":"Nekrose Und Autolyse.Beitrag Zur Kenntnis Der Dystrophischen\nVerkalkung","volume":"13","author":"Koller","year":"1934","journal-title":"Klin. Wochenschr."},{"key":"2026090216314999500_cit27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.mib.2014.06.015","article-title":"Reactive dirty fragments:\nimplications for tuberculosis drug discovery","volume":"21","author":"Gopal","year":"2014","journal-title":"Curr. Opin. Microbiol."},{"key":"2026090216314999500_cit28","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1128\/AAC.01370-15","article-title":"Selective\nInactivity of Pyrazinamide against Tuberculosis in C3HeB\/FeJ Mice\nIs Best Explained by Neutral pH of Caseum","volume":"60","author":"Lanoix","year":"2016","journal-title":"Antimicrob.\nAgents Chemother."},{"key":"2026090216314999500_cit29","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/imr.12252","article-title":"Heterogeneity in tuberculosis pathology,\nmicroenvironments and therapeutic responses","volume":"264","author":"Lenaerts","year":"2015","journal-title":"Immunol Rev."},{"key":"2026090216314999500_cit30","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1021\/acsinfecdis.5b00127","article-title":"Bedaquiline\nand Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion\nHeterogeneity in Mycobacterium tuberculosis Infected\nC3HeB\/FeJ. Mice","volume":"2","author":"Irwin","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"2026090216314999500_cit31","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1128\/AAC.03085-15","article-title":"High systemic exposure of pyrazinoic\nacid has limited anti-tuberculosis activity in murine and rabbit models\nof tuberculosis","volume":"60","author":"Lanoix","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090216314999500_cit32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms1060","article-title":"A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in\nvivo efficacy","volume":"1","author":"Pethe","year":"2010","journal-title":"Nat. Commun."},{"key":"2026090216314999500_cit33","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1021\/cb300151m","article-title":"Identification of Novel Inhibitors\nof M. tuberculosis Growth Using Whole Cell Based\nHigh-Throughput Screening","volume":"7","author":"Stanley","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"2026090216314999500_cit34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/47042","article-title":"Complex lipid determines tissue-specific replication\nof Mycobacterium tuberculosis in mice","volume":"402","author":"Cox","year":"1999","journal-title":"Nature"},{"key":"2026090216314999500_cit35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1365-2958.1999.01593.x","article-title":"Identification\nof a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis","volume":"34","author":"Camacho","year":"1999","journal-title":"Mol. Microbiol."},{"key":"2026090216314999500_cit36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1365-2958.2005.04524.x","article-title":"The pyruvate\nrequirement of some members of the Mycobacterium tuberculosis complex\nis due to an inactive pyruvate kinase: implications for in vivo growth","volume":"56","author":"Keating","year":"2005","journal-title":"Mol. Microbiol."},{"key":"2026090216314999500_cit37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1002\/prot.21126","article-title":"Crystal structure of uncleaved L-aspartate-\u03b1-decarboxylase\nfrom Mycobacterium tuberculosis","volume":"65","author":"Gopalan","year":"2006","journal-title":"Proteins: Struct., Funct., Genet."},{"key":"2026090216314999500_cit38","first-page":"761","article-title":"In vitro studies\non isonicotinic acid hydrazide","volume":"65","author":"Pansy","year":"1952","journal-title":"Am. Rev. Tuberc."},{"key":"2026090216314999500_cit39","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1128\/AAC.48.4.1289-1294.2004","article-title":"Effect of rpoB Mutations Conferring Rifampin Resistance\non Fitness of Mycobacterium tuberculosis","volume":"48","author":"Mariam","year":"2004","journal-title":"Antimicrob.\nAgents Chemother."},{"key":"2026090216314999500_cit40","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1128\/AAC.01369-06","article-title":"Pyrazinoic Acid\nand Its n-Propyl Ester Inhibit Fatty Acid Synthase Type I in Replicating\nTubercle Bacilli","volume":"51","author":"Zimhony","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026090216314999500_cit41","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1073\/pnas.93.10.4787","article-title":"Targeted replacement of the mycocerosic acid synthase\ngene in Mycobacterium bovis BCG produces a mutant that lacks mycosides","volume":"93","author":"Azad","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026090216314999500_cit42","doi-asserted-by":"publisher","first-page":"16741","DOI":"10.1074\/jbc.272.27.16741","article-title":"Gene Knockout Reveals a Novel Gene Cluster for the\nSynthesis of a Class of Cell Wall Lipids Unique to Pathogenic Mycobacteria","volume":"272","author":"Azad","year":"1997","journal-title":"J. Biol. Chem."},{"key":"2026090216314999500_cit43","doi-asserted-by":"publisher","first-page":"19845","DOI":"10.1074\/jbc.M100662200","article-title":"Analysis of the Phthiocerol Dimycocerosate Locus ofMycobacterium\ntuberculosis: EVIDENCE THAT THIS LIPID IS INVOLVED IN THE CELL WALL\nPERMEABILITY BARRIER","volume":"276","author":"Camacho","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2026090216314999500_cit44","first-page":"391","article-title":"Lack of significant\nin vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide\non three different solid media","volume":"67","author":"Tarshis","year":"1953","journal-title":"Am. Rev. Tuberc."},{"key":"2026090216314999500_cit45","first-page":"523","article-title":"Pyrazinamide\n(aldinamide) in the treatment of pulmonary tuberculosis","volume":"65","author":"Yeager","year":"1952","journal-title":"Am. Rev. Tuberc."},{"key":"2026090216314999500_cit46","first-page":"511","article-title":"The effect of pyrazinamide (aldinamide) on experimental\ntuberculosis in mice","volume":"65","author":"Malone","year":"1952","journal-title":"Am. Rev. Tuberc."},{"key":"2026090216314999500_cit47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2164-15-308","article-title":"Genome-wide\nMycobacterium tuberculosis variation (GMTV) database: a new tool for\nintegrating sequence variations and epidemiology","volume":"15","author":"Chernyaeva","year":"2014","journal-title":"BMC Genomics"},{"key":"2026090216314999500_cit48","doi-asserted-by":"publisher","first-page":"e0117771","DOI":"10.1371\/journal.pone.0117771","article-title":"Whole Genome Sequencing Based Characterization of Extensively Drug-Resistant Mycobacterium tuberculosis Isolates from Pakistan","volume":"10","author":"Ali","year":"2015","journal-title":"PLoS One"},{"key":"2026090216314999500_cit49","doi-asserted-by":"publisher","first-page":"e74082","DOI":"10.1371\/journal.pone.0074082","article-title":"Host Targeted Activity of Pyrazinamide in Mycobacterium\ntuberculosis Infection","volume":"8","author":"Manca","year":"2013","journal-title":"PLoS One"},{"key":"2026090216314999500_cit50","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4172\/2161-1068.1000145","article-title":"Revisiting Anti-tuberculosis Activity of Pyrazinamide\nin Mice","volume":"4","author":"Almeida","year":"2014","journal-title":"Mycobac Dis"},{"key":"2026090216314999500_cit51","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1099\/0022-1317-51-1-42","article-title":"Conditions that may\naffect the results of susceptibility testing of Mycobacterium tuberculosis\nto pyrazinamide","volume":"51","author":"Zhang","year":"2002","journal-title":"J. Med. Microbiol."},{"key":"2026090216314999500_cit52","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1128\/JCM.03197-12","article-title":"Evaluation of Methods\nfor Testing the Susceptibility of Clinical Mycobacterium tuberculosis\nIsolates to Pyrazinamide","volume":"51","author":"Cui","year":"2013","journal-title":"J. Clin Microbiol"},{"key":"2026090216314999500_cit53","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1128\/AEM.01358-08","article-title":"Optimized Method for Preparation\nof DNA from Pathogenic and Environmental Mycobacteria","volume":"75","author":"Ka\u0308ser","year":"2009","journal-title":"Appl. Environ. Microbiol."},{"key":"2026090216314999500_cit54","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/351456a0","article-title":"New use\nof BCG for recombinant vaccines","volume":"351","author":"Stover","year":"1991","journal-title":"Nature"},{"key":"2026090216314999500_cot55","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.1073\/pnas.0610634104","article-title":"Lipidomics reveals control of Mycobacterium","volume":"104","author":"Jain","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026090216314999500_cit56","first-page":"181","volume-title":"Methods\nin Enzymology","author":"Bachmann","year":"2009"}],"container-title":["ACS Infectious\nDiseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsinfecdis.6b00070","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/2\/9\/616\/67003509\/acsinfecdis.6b00070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/2\/9\/616\/67003509\/acsinfecdis.6b00070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:31:55Z","timestamp":1788381115000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article\/2\/9\/616\/783083\/Pyrazinamide-Resistance-Is-Caused-by-Two-Distinct"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,11]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,7,11]]},"published-print":{"date-parts":[[2016,9,9]]}},"URL":"https:\/\/doi.org\/10.1021\/acsinfecdis.6b00070","relation":{},"ISSN":["2373-8227"],"issn-type":[{"value":"2373-8227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,11]]}}}